The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available in 180mg and 360mg strengths.

"This approval further adds to Biocon's portfolio of vertically integrated complex drug products,” the company said in a statement.

Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune.

The company's consolidated net profit fell 18.3% to Rs 159.70 crore on a 5.2% increase in net sales to Rs 1,840.40 crore in Q2 September 2021 over Q2 September 2020.

The scrip shed 0.11% to currently trade at Rs 366.85 on the BSE.